story of the week
Famitinib With Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial
Clin. Cancer Res 2022 Mar 03;[EPub Ahead of Print], L Chen, YZ Jiang, SY Wu, J Wu, GH Di, GY Liu, KD Yu, L Fan, JJ Li, YF Hou, Z Hu, CM Chen, XY Huang, AY Cao, X Hu, S Zhao, XY Ma, Y Xu, XJ Sun, WJ Chai, X Guo, X Chen, Y Xu, XY Zhu, JJ Zou, WT Yang, ZH Wang, ZM ShaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.